Hepatitis C rate may be underestimated in UK

Key points
- More than half a million people in Britain may be infected with hepatitis C - two or three times the official estimates - a liver disease specialist warned on Wednesday.
- William Rosenberg, professor of medicine at Southampton University, told APM he had alerted the Department of Health to his findings, which are based on a new mathematical analysis and are being submitted for publication.
- He said the problem with the official estimates was they did not give enough weight to the way hepatitis C infection is clustered in high-risk groups and is virtually non-existent in other groups.
- The new model assessed the prevalence of the virus among drug users, prisoners, healthcare workers, blood product recipients and people who had attended sexually transmitted disease clinics.
More than half a million people in Britain may be infected with hepatitis C - two or three times the official estimates - a liver disease specialist warned on Wednesday.
William Rosenberg, professor of medicine at Southampton University, told APM he had alerted the Department of Health to his findings, which are based on a new mathematical analysis and are being submitted for publication.
He said the problem with the official estimates was they did not give enough weight to the way hepatitis C infection is clustered in high-risk groups and is virtually non-existent in other groups.
The new model assessed the prevalence of the virus among drug users, prisoners, healthcare workers, blood product recipients and people who had attended sexually transmitted disease clinics. The prevalence figures were then multiplied by the estimated number of people in these groups to give the overall population prevalence.
The results suggest that, as in France, somewhere around 1.2% of the British population may be infected compared with the 0.4% assumed by the UK Health Protection Agency.
"We are seeing twice the number of cases that we would expect if the official estimates were right," said Professor Rosenberg, who also works as a physician at Southampton General Hospital.
He warned that action was needed to prevent a "huge epidemic" of people developing end-stage liver failure and requiring transplantation over the next 20 years.
"The problem is that many people look at these risks and don't think it applies to them," Rosenberg told the Independent newspaper. "But there is a huge cohort of people who 20 or 30 years ago may have dabbled in drugs, even just once at a party, who could be infected.
"They are the ones who could have had the virus for 20 or 30 years now and could soon start developing end-stage liver disease."
So far, only 60,000 chronic carriers have been diagnosed in Britain and only 3,000 are receiving anti-viral therapy.
Last December, the health department launched a 2-million pound (2.9 million euros) campaign to encourage people who may have been exposed to the virus to get themselves tested.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsPrevalence of hepatitis C infection found to vary widely among Hispanics
The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected.…
14 January 2014
NewsText messaging boosts flu vaccine rates in pregnant women
A study by researchers at the Mailman School of Public Health evaluated the impact of text messaging reminders for influenza vaccine in a low-income obstetric population. The findings showed that sending text messages…
11 January 2014
NewsUNC research demonstrates 'guided missile' strategy to kill hidden HIV
Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill. Using mouse models that have immune…

